NASDAQ:TECX Tectonic Therapeutic Q4 2025 Earnings Report $24.98 -1.52 (-5.74%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$24.92 -0.06 (-0.23%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tectonic Therapeutic EPS ResultsActual EPS-$1.03Consensus EPS -$1.11Beat/MissBeat by +$0.08One Year Ago EPSN/ATectonic Therapeutic Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATectonic Therapeutic Announcement DetailsQuarterQ4 2025Date2/26/2026TimeBefore Market OpensConference Call DateThursday, February 26, 2026Conference Call Time3:00PM ETUpcoming EarningsTectonic Therapeutic's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tectonic Therapeutic Earnings HeadlinesTectonic Therapeutic (NASDAQ:TECX) Cut to Strong Sell at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.September 24 at 1:00 AM | Behind the Markets (Ad)Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull CaseSeptember 2, 2026 | seekingalpha.comStifel Nicolaus Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)August 13, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)August 7, 2026 | theglobeandmail.comSee More Tectonic Therapeutic Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tectonic Therapeutic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tectonic Therapeutic and other key companies, straight to your email. Email Address About Tectonic TherapeuticTectonic Therapeutic (NASDAQ:TECX) is a clinical-stage biotechnology company focused on developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in many physiological processes but have historically been difficult to address with conventional antibody-based therapies. The company uses its proprietary GEODe platform to discover and develop antibodies and other biologics designed to modulate GPCR activity. Tectonic’s pipeline includes TX45, an investigational therapeutic intended to activate the relaxin receptor RXFP1. The company is evaluating this program for potential use in cardiovascular diseases, including heart failure with preserved ejection fraction and other conditions associated with impaired vascular function. Tectonic Therapeutic was founded in 2019 and is headquartered in the United States. Its research and development activities are focused on advancing GPCR-directed biologics through clinical development, with the goal of addressing significant unmet medical needs in cardiovascular and other disease areas.View Tectonic Therapeutic ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
